Our research themes


Imperial College London is running a qualitative research project (meaning there are no medications to take) to understand people's views of screening and early treatment in pulmonary fibrosis to help develop an effective screening programme.   This project is called POSTPF. 

You may be able to participate if you: 

  • Have a diagnosis of pulmonary fibrosis   
  • Are the first-degree relative (parent, sibling, child) of a person diagnosed with pulmonary fibrosis
  • Have participated in screening for lung cancer  (called lung health check in the UK)
  • Are a healthcare professional working with people with pulmonary fibrosis for three or more years

The study involves sharing your views in a one-to-one interview (approx. 60 minutes) via remote video call (Teams or Zoom). The discussion will be recorded and transcribed, and a face-to-face interview will be available for those living in London. 

This research project is funded by the National Institute for Health and Care Research (NIHR).

If you are interested in taking part or would like more information about this study, please email postpfstudy@imperial.ac.uk 


These projects are performed in partnership with the Genomics England Clinical Interpretation Partnership and aim to understand the role of rare and common genetic variants in the cause and progression of pulmonary fibrosis. 

Fundamental Biology 

Defining Endotypes of pulmonary fibrosis (John and Jenkins). This project focuses on the function consequences of genetic abnormalities that are being identified as risk factors for Idiopathic Pulmonary Fibrosis and determining the severity of the disease. The focus of these study will be to understand the molecular consequences in alveolar epithelial cells and fibroblasts and the work funded by the Medical Research Council. 

Biomarker Development

Developing a biomarker guided strategy to treat patients with pulmonary fibrosis Cohort Studies (Stewart and Jenkins). The project uses data obtained from a range of cohort studies including the PROFILE, INJUSTIS, SUMMIT and Long COVID ILD studies and is funded by the NIHR. It aims to use big data strategies to determine whether serum biomarkers can be used to help decide when to start therapy for fibrotic lung disease.  

FUTURE Fibrosis Study (Fabbri and Jenkins). This project involves qualitative research preparing the foundations for a feasibility study to determine whether asymptomatic people at risk of progressive pulmonary fibrosis would be able to take preventative anti-fibrotic therapy. 

Drug Development 

Development of inhaled, dual EP2/4 receptor agonists for the treatment of idiopathic pulmonary fibrosis. This project is funded by the MRC Biomedical Catalyst Developmental Pathway Funding Scheme (Professor Charlton University of Nottingham) and will involve assessing the pre-clinical efficacy of a dual EP2/4 receptor agonist in a range of experimental models of pulmonary fibrosis.  

Post COVID Pulmonary Fibrosis

The UK Interstitial Lung Disease Post-COVID19 study (UKILD-Post COVID) aims to understand how much lung fibrosis will occur following COVID-19. The XMAS study (Lead Prof Wild University of Sheffield) looks at the ability of Xenon MRI to detect subtle perfusion abnormalities in the lungs of patients who have suffered from COVID-19. The POSTCODE study (Lead Dr Molyneaux NHLI) will use ‘omic technologies to identify the cellular and molecular changes that are associated with resolution or progression of inflammation and fibrosis following COVID-19.  This project is funded by the Medical Research Council to investigate the prevalence of post COVID Interstitial Lung Disease and the biological mechanisms that lead to the development of scarring following SAR-CoV-2 infection.

Multi-Morbid Fibrotic Disease

Idiopathic pulmonary fibrosis is associated with a range of different chronic fibrotic diseases such as Connective Tissue Diseases, Ischaemic Heart Disease, Chronic Kidney Disease, Chronic Liver Disease and Myelofibrosis. The DEMISTIFI consortium, funded by an MRC-NIHR Strategic Priority Fund, has been established to investigate the genetic, biological and clinical features that may lead to the development of fibrotic diseases across a range of multi-organ diseases. 


An inclusive collaborative project bringing together experts in fibrotic ILD (researchers, clinicians, patients, industry) to develop an adaptive platform trial which will identify treatments faster. Led by Professor Gisli Jenkins and funded by NIHR Efficacy and Mechanism Evaluation (EME) Accelerator Award – International platform studies in precision medicine REMAP-ILD.

Clinical trials

Cough Studies

  • Patients can participate on BOTH studies if washout periods are adhered to
  • Participants need to have had a chronic cough >8 weeks
  • Cough frequency is measured objectively using digital cough monitors

CANAL – sponsored by Trevi Therapeutics

A phase 2, double-blind, Randomized, placebo-controlled, two-treatment, two-period crossover efficacy and safety study in idiopathic pulmonary fibrosis with Nalbuphine ER tablets for the treatment of cough.

PAciFy Cough – sponsored by Royal Brompton Hospital

A multi-centre, double blind, placebo controlled, crossover trial of morphine sulfate for the treatment of pulmonary fibrosis cough (Phase III).

Anti-fibrotic Studies

BMS-986278 – sponsored by Bristol-Myers Squibb

A multi-centre, randomized, double-blind, placebo-controlled, phase 2 study of the efficacy and the safety and tolerability of BMS-986278 in participants with pulmonary fibrosis.

INTEGRIS-IPF – sponsored by Pliant Therapeutics

A randomized, double-blind, dose-ranging, placebo-controlled phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF).

Vicore - sponsored by Pharma AB

A phase 2, multi-centre, open-label, single-arm trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis (IPF).


Through understanding the clusters of Fibrotic Multi-Morbidity and mapping them to the mechanisms of available therapies, the DEMISTIFI consortium will aim to prevent the development of long term Fibrotic Multi-Morbidity. Find out more on UKRI webpages.